These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector. Roy S; Shirley PS; Connelly S; Andrews JL; Kayda DB; Gardner JM; Kaleko M Haemophilia; 1999 Sep; 5(5):340-8. PubMed ID: 10583516 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII. Rea C; Dunkerley A; Sørensen B; Rangarajan S Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015 [TBL] [Abstract][Full Text] [Related]
12. Expression and characterization of a codon-optimized blood coagulation factor VIII. Shestopal SA; Hao JJ; Karnaukhova E; Liang Y; Ovanesov MV; Lin M; Kurasawa JH; Lee TK; Mcvey JH; Sarafanov AG J Thromb Haemost; 2017 Apr; 15(4):709-720. PubMed ID: 28109042 [TBL] [Abstract][Full Text] [Related]
13. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Connelly S; Smith TA; Dhir G; Gardner JM; Mehaffey MG; Zaret KS; McClelland A; Kaleko M Hum Gene Ther; 1995 Feb; 6(2):185-93. PubMed ID: 7537539 [TBL] [Abstract][Full Text] [Related]
14. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A. Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367 [TBL] [Abstract][Full Text] [Related]
15. Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter. Fong S; Handyside B; Sihn CR; Liu S; Zhang L; Xie L; Murphy R; Galicia N; Yates B; Minto WC; Vitelli C; Harmon D; Ru Y; Yu GK; Escher C; Vowinckel J; Woloszynek J; Akeefe H; Mahimkar R; Bullens S; Bunting S Mol Ther Methods Clin Dev; 2020 Sep; 18():620-630. PubMed ID: 32775496 [TBL] [Abstract][Full Text] [Related]
16. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333 [TBL] [Abstract][Full Text] [Related]
17. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. Chen H; Shi M; Gilam A; Zheng Q; Zhang Y; Afrikanova I; Li J; Gluzman Z; Jiang R; Kong LJ; Chen-Tsai RY Sci Rep; 2019 Nov; 9(1):16838. PubMed ID: 31727959 [TBL] [Abstract][Full Text] [Related]
18. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327 [TBL] [Abstract][Full Text] [Related]